BridgeMD
A clinical phase IV trial to examine cellular and humoral immunity against measles and chickenpox in children and adolescents 0-18 years in childhood cancer.
EU CTIS ID: 2024-511182-10-01
What this study is testing
Primary aim 1) Immunity after revaccination with vaccine aganist varicella, after treatment against childhood cancer. Measured by IgG antibodies to VZV before and after vaccination. (Proportion (%) of patients with protective level of VZ-IgG after vaccination – proportion (%) of patients with protective level of VZ-IgG before vaccination). 2) Immunity after revaccination with vaccine against measles, after treatment against childhood cancer. Measured by IgG antibodies to morbilli before and after vaccination. (Proportion (%) of patients with protective morbilli-IgG level after vaccination – proportion (%) of patients with protective morbilli-IgG level prior to vaccination).
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Children and adolescents (0-18.0 years) initiating cancer treatment through the childrens cancer centre in Gothenburg.
- Vaccination status for measles and chickenpox before cancer treatment is known.
- Oral and written information about the trial along with signed consent
- Female participants of reproductive age with menarche who are sexually active must consent to using effective contraception and have a negative pregnancy test at the times of all vaccinations. (Effective contraception refers to combined preparations with estrogen and progesterone taken orally, intravaginal ring, known as the p-ring, or preparations used transdermally, such as the contraceptive patch. Contraception with progesterone taken orally, via injections, or implants such as the contraceptive implant. Intrauterine hormone-releasing coil or copper coil. Completed sterilization with blockage of both fallopian tubes. Sexual abstinence)
You likely can't join if
- Known primary immunodeficiency.
- Ongoing treatment with immunomodulatory or immunosuppressive agents
- Patients planned for relapse therapy or stem cell transplantation (SCT)
- Known contraindication to any of the proposed vaccines.
- Female participants with an ongoing pregnancy at diagnosis or during the study
- Ongoing breastfeeding.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.